Navigation Links
Patient Recruitment Begins in India for Phase 3 Diabetes Trial
Date:11/7/2008

BETHESDA, Md., Nov. 7 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX) reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose(R), has begun in India. Expectations for India are to provide more than 300 patients spread across 35 sites for the pivotal Phase 3 trial. "Now that enrollment efforts are underway in India, we believe that the Phase 3 trial will be completed on schedule as reported during the May 2008 Annual Shareholders Meeting. This truly represents a tremendous amount of hard work, both internally and externally, to achieve regulatory approval and patient recruitment in such a short period of time," said Randy W. Brown, Chief of Operations. Global enrollment is scheduled for completion by the end of the first quarter 2009, and the trial is scheduled to be completed in 2010.

Spherix Incorporated also announced the signing of a contract with Amarex, a Contract Research Organization (CRO) located in Germantown, MD, to oversee the work of two India CROs hired to execute the trial in India.

"It became quite clear that the trial was not executable solely in the United Sates with our known parameters; therefore, India became an obvious, viable solution. I now expect our ultimate deliverable, a new drug application, to be back on schedule," said Mr. Brown.

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those
'/>"/>

SOURCE Spherix Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
2. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
3. Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
4. New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
5. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
6. Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
7. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
8. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
9. Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
10. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
11. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... The potential of the pulmonary ... therapeutic agents has been receiving undeniable attention with the ... promise. The crucial formulation considerations for orally inhaled products ... major role in the efficiency of pulmonary delivery, and ... new formulation techniques and devices in recent years. ...
(Date:5/23/2013)... 24, 2013 3SBio Inc. (NASDAQ: ... leading China -based biotechnology company ... products, announced today that, at an extraordinary general ... voted in favor of the proposal to authorize ... of merger dated February 8, 2013, among Decade ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de ... ), un destacado desarrollador y fabricante de herramientas ... la diagnosis y tratamiento de la enfermedad vascular ... del ensayo ADVISE ( Ad enosine V ... E valuation) II durante la sesión de ensayo ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... (CellCyte) (OTC Bulletin Board: CCYG) has selected the,Cardiovascular ... St. Louis to perform a study to further ... is to investigate the efficiency of,CellCyte,s glycoprotein products ... "We look forward to working with the ...
... University of,California San Diego, reported today at the American ... on the use of a,new technology, Neucrylate(TM), to treat ... developed by Valor Medical, a San Diego, CA,medical device ... to,date the accumulated patient implant times have reached 1400 ...
Cached Medicine Technology:CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCyte's Glycoprotein Products in Heart Attack Disease Model 2CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCyte's Glycoprotein Products in Heart Attack Disease Model 3
(Date:5/24/2013)... 2013 This week is National EMS ... efforts to provide the best emergency care and to ... week is also to educate the public that all ... Citizens are the first link, and a very important ... CPR after a cardiac arrest can triple a victim’s ...
(Date:5/24/2013)... hospitalized for heart failure appear to have better odds ... the morning, a new study finds. Death rates ... patients admitted in January, on Fridays and overnight, according ... findings Saturday in Portugal at the annual meeting of ... Cardiology. "The fact that patients admitted right ...
(Date:5/24/2013)... KC and Monica Craichy, Founders of Living Fuel, Inc ... Kyle and Austin Craichy, will be kiteboarding with members of ... , KC Craichy said he is excited to be involved ... that virtually everyone who planned to be involved is going ... meet at Matheson Hammock Park and Beach in Miami at ...
(Date:5/24/2013)... News) -- New research suggests a link between ... insomnia. Every additional hour someone with insomnia ... in the likelihood of moderate or high risk ... of Pennsylvania. "We were surprised by ... and suicide risk," study author, Linden Oliver, clinical ...
(Date:5/24/2013)... OR (PRWEB) May 24, 2013 ... Sustainable Cards, major competitors in sustainable card material, ... of using forest materials as a sustainable gift ... is to identify industry challenges and increase education ... card programs to support the reduction of carbon ...
Breaking Medicine News(10 mins):Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3
... -- How best to alleviate chronic pain, a leading ... both patients and their doctors. , A review ... June 2008 issue of the Journal of General Internal ... therapies to treat pain have advantages and disadvantages, researchers ...
... Week, June 9-13, National Leaders Convene to ... The following media,advisory was issued today by ... http://www.newscom.com/cgi-bin/prnh/20060801/CGTU009LOGO-a ), WHAT:, HIMSS ... June 9-10,2008. The Healthcare Information and Management Systems ...
... wear head protection, study says , , THURSDAY, June ... should wear headgear on the field to protect them ... , At the very least, players should consider wearing ... acknowledges that changing the culture of baseball may be ...
... Robust Pipelines Across Seven MD&D Franchises Poised to Deliver Innovation ... ... on Superior Science and Technology, NEW BRUNSWICK, N.J., June 5 ... at a,meeting with the investment community today, focusing on the strengths,strategies and ...
... Regional Medical,Foundation (SRMF) announces that its Vacaville care ... tool in screening for breast,cancer., Digital mammography, ... of the,most effective weapons in the fight against ... image quality is superior, with at least a ...
... out of five,disability income insurance claimants are satisfied ... by Harris Interactive on behalf of,America,s Health Insurance ... "Disability insurers are providing valuable income protection ... needs of disabled,workers," said Karen Ignagni, President and ...
Cached Medicine News:Health News:How best to treat chronic pain? The jury is still out 2Health News:HIMSS Summit08 and Advocacy Day 2Health News:Batted Balls Threaten High School Baseball Players 2Health News:Batted Balls Threaten High School Baseball Players 3Health News:Johnson & Johnson Reviews Growth Strategies for Medical Devices & Diagnostics and Consumer Businesses 2Health News:Johnson & Johnson Reviews Growth Strategies for Medical Devices & Diagnostics and Consumer Businesses 3Health News:Johnson & Johnson Reviews Growth Strategies for Medical Devices & Diagnostics and Consumer Businesses 4Health News:Johnson & Johnson Reviews Growth Strategies for Medical Devices & Diagnostics and Consumer Businesses 5Health News:Johnson & Johnson Reviews Growth Strategies for Medical Devices & Diagnostics and Consumer Businesses 6Health News:Johnson & Johnson Reviews Growth Strategies for Medical Devices & Diagnostics and Consumer Businesses 7Health News:Johnson & Johnson Reviews Growth Strategies for Medical Devices & Diagnostics and Consumer Businesses 8Health News:Advanced Digital Mammography System Comes to Vacaville 2Health News:Four Out of Five Disability Income Insurance Claimants are Satisfied With Their Policy 2Health News:Four Out of Five Disability Income Insurance Claimants are Satisfied With Their Policy 3
... Total Knee System provides the adaptability surgeons ... patient. Not the other way around. The ... inserts and patellar components allow surgeons to ... you do it all with one instrument ...
... new implant. It's a new material, exclusively ... can be greatly reduced . The nickel ... of the nickel-sensitive patient. Hardness, lubricity and ... is available in our two already proven ...
... TC-PLUS Solution tricompartmental total knee prosthesis stems ... arthroplasty. State-of-the-art design and manufacturing technologies have ... biomechanical function as well as a favorable ... insert to keep wear to a minimum. ...
Cementless hip system...
Medicine Products: